Based on work that began in the 1990s, UT Southwestern researchers “solved the HIF-2α protein structure, pinpointing a potential vulnerability” in the gene, according to a news release from the medical center.
The researchers then formed Peloton Therapeutics to develop and test belzutifan. Merck acquired Peloton in 2019, and the FDA approved the drug for a familial kidney cancer condition in 2021. About two years later, the approved label grew to include anyone with advanced renal cell carcinoma — the most common type of kidney cancer.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
